Evidence map›Paper›PMID 40999034›Full record

ArticleJournal of neurology2025

Apraxic deficits predict general cognitive impairment in patients with biomarker-verified Alzheimer's pathology.

Claudia C Schmidt, Michella M Bardakan, Elena Jaeger, Nils Richter, Gérard N Bischof, Kathrin Giehl, Oezguer A Onur, Frank Jessen, Gereon R Fink, Alexander Drzezga and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Claudia C SchmidtCognitive Neuroscience, Institute of Neurosciences and Medicine (INM-3), Forschungszentrum Jülich, Jülich, Germany. c.schmidt@fz-juelich.de.ORCID http://orcid.org/0000-0002-1296-577X
Michella M BardakanCognitive Neuroscience, Institute of Neurosciences and Medicine (INM-3), Forschungszentrum Jülich, Jülich, Germany.
Elena JaegerDepartment of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Nils RichterCognitive Neuroscience, Institute of Neurosciences and Medicine (INM-3), Forschungszentrum Jülich, Jülich, Germany.
Gérard N BischofDepartment of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Kathrin GiehlDepartment of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Oezguer A OnurCognitive Neuroscience, Institute of Neurosciences and Medicine (INM-3), Forschungszentrum Jülich, Jülich, Germany.
Frank JessenDepartment of Psychiatry and Psychotherapy, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Gereon R FinkCognitive Neuroscience, Institute of Neurosciences and Medicine (INM-3), Forschungszentrum Jülich, Jülich, Germany.
Alexander DrzezgaDepartment of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Peter H WeissCognitive Neuroscience, Institute of Neurosciences and Medicine (INM-3), Forschungszentrum Jülich, Jülich, Germany.

Funding

Deutsche Forschungsgemeinschaft SFB 1451 - 431549029
6 · The paper itself

Abstract

Apraxia represents a core feature of Alzheimer's disease (AD), a neurodegenerative disorder characterised by the accumulation of β-amyloid plaques and tau deposition. However, systematic descriptions of apraxic deficits in AD patients remain scarce. Here, we comprehensively investigate apraxia profiles and their link with cognitive impairment in patients with biomarker-verified Alzheimer's pathology. We characterised the frequency and patterns of apraxic deficits in patients with biomarker-verified Alzheimer's pathology using a battery of standardised apraxia tests. Demographic variables and apraxia scores were related to patients' general cognitive impairment using hierarchical regression analysis. Apraxic deficits were found in 67% of patients with biomarker-verified Alzheimer's pathology (n = 63). Patients with Alzheimer's pathology were more impaired in imitating finger gestures (than hand gestures: 89.2% vs. 80.0%, p < 0.001) and imitating complex hand movements (than single hand movements: 97.4% vs. 78.5%, p < 0.001), even when controlling for general cognitive impairment. Apraxia assessments explained about 60% of the variance in dementia severity, with performance in the KAS subtest of pantomiming object use (beta coefficient: 0.47, p = 0.001) and the DATE subtest for limb apraxia (beta coefficient: 0.37, p = 0.005) constituting significant predictors of general cognitive impairment. These findings emphasise the relevance of apraxia in patients with biomarker-verified Alzheimer's pathology, revealing that praxis deficits predict general cognitive impairment in AD. Further research is warranted into the role of apraxia as a potential early diagnostic criterion in AD.

Indexed as

Alzheimer DiseaseApraxiasCognitive DysfunctionAgedAged, 80 and overBiomarkersFemaleGesturesHumansMaleMiddle AgedNeuropsychological TestsBiomarkersAlzheimer’s diseaseGesture imitationLimb apraxiaMini-Mental State Examination (MMSE)Pantomime

Identifiers

PMID40999034
PMCPMC12464036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.